Education · Tier 5

· Last Reviewed May 15, 2026· PSI Editorial Board· Independent

How Are Peptide Therapy Protocols Designed?

The conceptual reference for peptide therapy protocol framework anchored in FDA prescribing information duration limits and AMA Code of Medical Ethics 1.1.5.

Peptide therapy protocols are designed by the prescribing physician.

The framework anchors in FDA prescribing information for FDA-approved peptide drugs.

Duration limits and sequential therapy frameworks apply per the FDA label.

FDA Label

Duration Anchoring

FDA prescribing information specifies duration limits for FDA-approved peptide drugs including anabolic osteoporosis class

Lifetime Max

Anabolic Osteoporosis

Forteo teriparatide and Tymlos abaloparatide have cumulative lifetime maximums per FDA label

Sequential

Anti-Resorptive Transition

Evenity romosozumab uses fixed monthly schedule with anti-resorptive transition after completion

Physician

Protocol Decisions

The physician determines protocol design, duration, and sequential therapy per FDA prescribing information

Quick Answer

Peptide therapy protocol design is determined by the prescribing physician. The framework anchors in FDA prescribing information for approved peptides and AMA Code 1.1.5 for compounded preparations. This page provides conceptual education only.

The FDA prescribing information for each FDA-approved peptide drug specifies duration framework. The anabolic osteoporosis peptide class has FDA-label-specified cumulative lifetime maximums. Teriparatide (Forteo NDA 021318) has a cumulative lifetime maximum per FDA label. Abaloparatide (Tymlos NDA 208743) has a cumulative lifetime maximum per FDA label. Romosozumab (Evenity NDA 761062 with cardiovascular boxed warning) uses a fixed monthly schedule per FDA label.

Sequential anti-resorptive transition follows anabolic peptide therapy. After completion of anabolic peptide therapy, AACE/ACE 2020 and Endocrine Society 2019 Postmenopausal Osteoporosis CPGs recommend transition to anti-resorptive therapy. Examples of anti-resorptive therapy include bisphosphonates (alendronate, risedronate, zoledronic acid) or denosumab. The transition supports continued fracture risk reduction after anabolic peptide therapy completion.

The GLP-1 receptor agonist class does not have FDA-label-specified cumulative maximums. Semaglutide (Wegovy NDA 215256, Ozempic NDA 209637) supports ongoing therapy per FDA label. Tirzepatide (Zepbound NDA 217806, Mounjaro NDA 215866) supports ongoing therapy per FDA label.

The four-stage monitoring cadence applies across the class. Baseline at week 0. Early follow-up at week 4 to 8. Stabilization at month 3. Maintenance at month 6 with annual continuation. The physician determines monitoring frequency per indication and FDA label.

For compounded peptide preparations, AMA Code 1.1.5 framework applies. The framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding. See The Compounding Pharmacy System for the regulatory framework. See Injection Protocols 101 for the route framework.

This page is conceptual education only. Protocol design must be determined by a qualified physician evaluating individual patient context.

The anabolic osteoporosis peptide class has FDA-label-specified cumulative lifetime maximums. Forteo teriparatide has a cumulative lifetime maximum per FDA label. Tymlos abaloparatide has a cumulative lifetime maximum per FDA label. Evenity romosozumab uses a fixed monthly schedule per FDA label with transition to anti-resorptive therapy after completion. The physician determines duration and sequential therapy per FDA prescribing information. AMA Code of Medical Ethics 1.1.5 governs off-label and compounded protocol decisions. This page is conceptual education only. Protocol design must be determined by a qualified physician.

PROTOCOL DESIGN REFERENCE

At a Glance: Cycling and Protocol Design

Framework Element	Subtitle	Animal Evidence	Human Evidence	Clinical Application
FDA prescribing information duration framework	Each FDA-approved peptide has a label-specified duration framework	—	Strong	Anabolic osteoporosis class has cumulative lifetime maximums. GLP-1 receptor agonist class supports ongoing therapy. Physician applies FDA label
Anabolic osteoporosis peptide lifetime maximums	Forteo and Tymlos cumulative lifetime maximums per FDA label	—	Strong	Forteo teriparatide (NDA 021318) and Tymlos abaloparatide (NDA 208743) have FDA-label-specified cumulative lifetime maximums. Physician applies framework
Evenity fixed monthly schedule	Sclerostin antibody framework with anti-resorptive transition	—	Strong	Evenity romosozumab (NDA 761062 with CV boxed warning) uses fixed monthly schedule per FDA label. Anti-resorptive transition after completion
Sequential anti-resorptive transition framework	Anti-resorptive therapy after anabolic peptide completion	—	Strong	AACE/ACE 2020 and Endocrine Society 2019 CPGs recommend bisphosphonate or denosumab transition. Physician applies framework per indication
GLP-1 receptor agonist ongoing therapy framework	No FDA-label-specified cumulative maximum for the class	—	Strong	Wegovy, Ozempic, Zepbound, Mounjaro support ongoing therapy per FDA label. SELECT 2023 demonstrated cardiovascular benefit with continued therapy
Four-stage monitoring cadence	Baseline, early follow-up, stabilization, maintenance	—	Strong	Baseline week 0, early follow-up week 4 to 8, stabilization month 3, maintenance month 6 with annual continuation. Physician-directed framework
AMA Code 1.1.5 framework for compounded preparations	Risk-benefit, alternatives, monitoring, informed consent	—	Moderate	Compounded peptide protocol decisions require AMA Code 1.1.5 documentation. Physician determines compounded protocol design
Physician-determined protocol design	Individualized per FDA label and patient context	—	Strong	PSI does not provide protocol design guidance or cycling instructions. Protocol design must be determined by qualified physician

Six Things You Need to Know About Peptide Protocol Design

This page covers peptide therapy protocol design conceptual framework. Section one covers FDA prescribing information duration limits across the FDA-approved peptide drug class. Section two covers anabolic osteoporosis peptide cumulative lifetime maximums and Evenity fixed monthly schedule. Section three covers sequential anti-resorptive transition per AACE/ACE 2020 and Endocrine Society 2019 CPGs. Section four covers the four-stage monitoring cadence and AMA Code 1.1.5 framework. This page is conceptual education only.

FDA Prescribing Information Specifies Duration Framework

FDA prescribing information specifies duration framework for each FDA-approved peptide drug. The label reflects Phase 3 trial evidence supporting FDA approval. The physician applies FDA label guidance to individual patient context.

FDA prescribing information specifies indication, dosing, route, schedule, and duration framework for each FDA-approved peptide drug. The label reflects Phase 3 trial evidence supporting FDA approval. The duration framework varies by peptide class and indication. The anabolic osteoporosis peptide class has cumulative lifetime maximums per FDA label. The GLP-1 receptor agonist class supports ongoing therapy per FDA label. Examples of FDA prescribing information duration framework include Wegovy semaglutide (NDA 215256) supporting ongoing chronic weight management therapy, Ozempic semaglutide (NDA 209637) supporting ongoing type 2 diabetes management, Zepbound tirzepatide (NDA 217806) supporting ongoing chronic weight management, Mounjaro tirzepatide (NDA 215866) supporting ongoing type 2 diabetes management, Forteo teriparatide (NDA 021318) specifying cumulative lifetime maximum framework, Tymlos abaloparatide (NDA 208743) specifying cumulative lifetime maximum framework, Evenity romosozumab (NDA 761062 with cardiovascular boxed warning) specifying fixed monthly schedule per FDA label, Tesamorelin Egrifta (NDA 022505) supporting ongoing therapy for HIV-associated lipodystrophy, and Vyleesi bremelanotide (NDA 210557) specifying on-demand framework. The physician determines individual patient duration per FDA label and clinical context.

Anabolic Osteoporosis Peptides Have Cumulative Lifetime Maximums

The anabolic osteoporosis peptide class has FDA-label-specified cumulative lifetime maximums. Forteo teriparatide (NDA 021318) has a cumulative lifetime maximum per FDA label. Tymlos abaloparatide (NDA 208743) has a cumulative lifetime maximum per FDA label.

The anabolic osteoporosis peptide class uses cumulative lifetime maximum framework per FDA prescribing information. Forteo teriparatide and Tymlos abaloparatide as PTH analogs have FDA-label-specified cumulative lifetime maximums. The framework reflects Phase 3 trial evidence and safety considerations. VERT NEJM 2001 (Neer et al.) anchored Forteo FDA approval with fracture reduction evidence. ACTIVE JAMA 2016 (Miller et al.) anchored Tymlos FDA approval with fracture reduction evidence. The cumulative lifetime maximum framework supports patient safety across the anabolic peptide class. The physician determines individual patient duration per FDA label and AACE/ACE 2020 Postmenopausal Osteoporosis CPG framework. The Endocrine Society 2019 Postmenopausal Osteoporosis CPG (Eastell et al.) provides additional framework. Sequential anti-resorptive therapy follows anabolic peptide completion per society CPG recommendation. PSI provides conceptual education only. Specific duration application must be determined by a qualified physician evaluating individual patient context.

Evenity Uses Fixed Monthly Schedule With Anti-Resorptive Transition

Evenity romosozumab (NDA 761062 with cardiovascular boxed warning) uses a fixed monthly schedule per FDA label. The framework specifies a defined treatment course followed by anti-resorptive transition per AACE/ACE 2020 and Endocrine Society 2019 CPGs.

Evenity romosozumab is the FDA-approved sclerostin antibody for postmenopausal osteoporosis with high fracture risk. The compound was anchored by FRAME NEJM 2016 (Cosman et al.) and ARCH NEJM 2017 (Saag et al.) Phase 3 trials. FDA approved Evenity in April 2019 with a cardiovascular boxed warning based on the ARCH trial cardiovascular safety findings. The FDA prescribing information specifies a fixed monthly schedule per FDA label. The framework reflects the unique dual-action mechanism: romosozumab increases bone formation and simultaneously decreases bone resorption. After completion of the defined Evenity course, sequential anti-resorptive therapy is recommended per AACE/ACE 2020 Postmenopausal Osteoporosis CPG and Endocrine Society 2019 CPG. Anti-resorptive options include bisphosphonates (alendronate, risedronate, zoledronic acid) or denosumab. The transition supports continued fracture risk reduction. The physician determines individual patient protocol per FDA label and society CPG framework. Specialty coordination with endocrinology and rheumatology supports complex contexts. PSI provides conceptual education only.

GLP-1 Receptor Agonists Support Ongoing Therapy Without Lifetime Maximum

The GLP-1 receptor agonist class supports ongoing therapy per FDA prescribing information without a label-specified cumulative lifetime maximum. SELECT 2023 demonstrated cardiovascular benefit with continued semaglutide therapy.

The GLP-1 receptor agonist class includes semaglutide (Wegovy NDA 215256 for chronic weight management, Ozempic NDA 209637 for type 2 diabetes), tirzepatide (Zepbound NDA 217806, Mounjaro NDA 215866), and liraglutide (Saxenda, Victoza). FDA prescribing information supports ongoing therapy without a label-specified cumulative lifetime maximum. The framework reflects Phase 3 trial evidence and cardiovascular outcomes evidence. SELECT 2023 NEJM (Lincoff et al.) demonstrated approximately 20 percent MACE reduction with semaglutide in obesity without diabetes over multi-year follow-up. SUSTAIN-6 NEJM 2016 (Marso et al.) demonstrated cardiovascular benefit of semaglutide in type 2 diabetes. LEADER NEJM 2016 (Marso et al.) demonstrated cardiovascular benefit of liraglutide in type 2 diabetes. The evidence supports continued therapy framework. Discontinuation typically results in weight regain and metabolic regression per Phase 3 trial extension evidence. The physician determines individual patient duration per FDA label, ADA 2024 Standards of Care framework, indication, and clinical context. Specialty coordination with endocrinology, weight medicine, primary care, or internal medicine supports complex contexts.

The Four-Stage Monitoring Cadence Applies Across the Class

The four-stage monitoring cadence applies across FDA-approved and compounded peptide therapy. Baseline at week 0. Early follow-up at week 4 to 8. Stabilization at month 3. Maintenance at month 6 with annual continuation thereafter.

The four-stage monitoring cadence supports systematic peptide therapy management across the class. Stage 1 baseline at week 0 establishes the indication-appropriate marker panel and AMA Code 1.1.5 documentation for compounded contexts. Stage 2 early follow-up at week 4 to 8 tracks tolerability, side effect emergence, and initial pharmacologic response. The window captures GLP-1 receptor agonist gastrointestinal tolerability assessment and other class-specific early signals. Stage 3 stabilization at month 3 captures steady-state pharmacologic response. The window supports any indication-appropriate adjustment decisions per FDA prescribing information. Stage 4 maintenance at month 6 with annual continuation thereafter applies the full panel re-check supporting long-term clinical management. The framework anchors physician-directed peptide therapy across the FDA-approved and compounded class. Indication-specific markers re-checked at each stage depend on peptide class per FDA prescribing information or AMA Code 1.1.5 documentation. The PSI bloodwork pages cluster provides indication-specific monitoring framework. See [Biomarker Interpretation](/education/biomarker-interpretation) for marker-specific framework.

Compounded Preparations Use AMA Code 1.1.5 Framework

Compounded peptide preparation protocol decisions operate under AMA Code of Medical Ethics 1.1.5 framework. The framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding through informed consent.

Compounded peptide preparations operate under the FDA Compounding Quality Act of 2013 without FDA pre-market approval. Protocol design for compounded preparations requires AMA Code 1.1.5 framework documentation. The framework requires documented risk-benefit assessment for the specific patient context. The framework requires documented FDA-approved alternatives considered per indication. The framework requires monitoring requirements including baseline labs and follow-up cadence. The framework requires patient understanding through informed consent acknowledgment. AMA Code 2.1.1 establishes the broader informed consent framework. Compounded peptide examples include compounded thymosin alpha-1 (international Zadaxin approval contexts), compounded BPC-157 and TB-500 (primarily preclinical evidence base), compounded sermorelin (growth hormone secretagogue context), and compounded cerebrolysin (international clinical evidence). The physician applying AMA Code 1.1.5 framework determines compounded preparation protocol, duration, and clinical context. PSI provides conceptual education only. See [The Compounding Pharmacy System](/education/the-compounding-pharmacy-system) for the regulatory framework. See [Evidence Levels Explained](/education/evidence-levels-explained) for the PSI four-tier framework.

Anabolic osteoporosis peptide cumulative lifetime maximum framework

Forteo and Tymlos FDA-label-specified maximums anchored in VERT and ACTIVE Phase 3 evidence

The anabolic osteoporosis peptide class uses cumulative lifetime maximum framework per FDA prescribing information. Forteo teriparatide (NDA 021318) and Tymlos abaloparatide (NDA 208743) as PTH analogs have FDA-label-specified cumulative lifetime maximums. The framework reflects Phase 3 trial evidence supporting FDA approval and ongoing safety considerations.

VERT NEJM 2001 (Neer et al. effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis) anchored Forteo FDA approval with fracture reduction evidence. ACTIVE JAMA 2016 (Miller et al. effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis) anchored Tymlos FDA approval with fracture reduction evidence. The cumulative lifetime maximum framework supports patient safety across the anabolic peptide class.

The physician determines individual patient duration per FDA label and AACE/ACE 2020 Postmenopausal Osteoporosis CPG framework. The Endocrine Society 2019 CPG (Eastell et al.) provides additional framework. Sequential anti-resorptive therapy follows anabolic peptide completion per society CPG recommendation. Anti-resorptive options include bisphosphonates (alendronate, risedronate, zoledronic acid) or denosumab. The transition supports continued fracture risk reduction. PSI provides conceptual education only. Specific duration application must be determined by a qualified physician evaluating individual patient context.

Evenity sclerostin antibody framework with cardiovascular boxed warning

Fixed monthly schedule per FDA label anchored in FRAME and ARCH Phase 3 evidence

Evenity romosozumab (NDA 761062 with cardiovascular boxed warning) is the FDA-approved sclerostin antibody for postmenopausal osteoporosis with high fracture risk. The compound was anchored by FRAME NEJM 2016 (Cosman et al.) and ARCH NEJM 2017 (Saag et al.) Phase 3 trials. FDA approved Evenity in April 2019. The cardiovascular boxed warning was based on the ARCH trial cardiovascular safety findings demonstrating increased serious cardiovascular adverse events compared to alendronate comparator.

The FDA prescribing information specifies a fixed monthly schedule per FDA label. The framework reflects the unique dual-action mechanism: romosozumab increases bone formation and simultaneously decreases bone resorption. The dual-action mechanism distinguishes Evenity from PTH analogs (Forteo, Tymlos) which increase both formation and resorption with greater formation. Bone turnover markers (P1NP increases, CTX decreases) reflect the dual-action mechanism per AACE/ACE 2020 monitoring framework.

After completion of the defined Evenity course, sequential anti-resorptive therapy is recommended per AACE/ACE 2020 Postmenopausal Osteoporosis CPG and Endocrine Society 2019 CPG. Anti-resorptive options include bisphosphonates or denosumab. The transition supports continued fracture risk reduction after anabolic completion. The physician determines individual patient protocol per FDA label and society CPG framework. Specialty coordination with endocrinology, rheumatology, and cardiology (given the boxed warning) supports complex contexts. PSI provides conceptual education only.

GLP-1 receptor agonist ongoing therapy framework with cardiovascular outcomes evidence

SELECT 2023 multi-year cardiovascular benefit anchoring continued semaglutide therapy

The GLP-1 receptor agonist class supports ongoing therapy per FDA prescribing information without a label-specified cumulative lifetime maximum. The class includes semaglutide (Wegovy NDA 215256 for chronic weight management, Ozempic NDA 209637 for type 2 diabetes), tirzepatide (Zepbound NDA 217806, Mounjaro NDA 215866), and liraglutide (Saxenda, Victoza). FDA prescribing information supports ongoing therapy framework reflecting Phase 3 trial evidence and cardiovascular outcomes evidence.

Cardiovascular outcomes evidence anchors the ongoing therapy framework. SELECT 2023 NEJM (Lincoff et al. semaglutide and cardiovascular outcomes in obesity without diabetes) demonstrated approximately 20 percent MACE reduction with semaglutide over multi-year follow-up in 17,604 patients with established cardiovascular disease and obesity without diabetes. SUSTAIN-6 NEJM 2016 (Marso et al. semaglutide and cardiovascular outcomes in patients with type 2 diabetes) demonstrated cardiovascular benefit of semaglutide in type 2 diabetes. LEADER NEJM 2016 (Marso et al. liraglutide and cardiovascular outcomes in type 2 diabetes) demonstrated cardiovascular benefit of liraglutide in type 2 diabetes.

Discontinuation typically results in weight regain and metabolic regression per Phase 3 trial extension evidence. The STEP-4 extension trial demonstrated weight regain after semaglutide discontinuation supporting the chronic disease management framework rather than time-limited intervention framework. The physician determines individual patient duration per FDA label, ADA 2024 Standards of Care framework for type 2 diabetes contexts, indication, and clinical context. Specialty coordination with endocrinology, weight medicine, primary care, or internal medicine supports complex contexts.

Research Suggests

Direction

Peptide therapy protocol design follows FDA prescribing information for FDA-approved peptides and AMA Code 1.1.5 framework for compounded preparations. The physician determines all protocol design decisions.

The anabolic osteoporosis peptide class has FDA-label-specified cumulative lifetime maximums for Forteo teriparatide and Tymlos abaloparatide. Evenity romosozumab uses fixed monthly schedule per FDA label with anti-resorptive transition after completion. The GLP-1 receptor agonist class supports ongoing therapy per FDA label without label-specified cumulative maximum. Sequential anti-resorptive transition follows anabolic peptide therapy completion per AACE/ACE 2020 and Endocrine Society 2019 CPGs. The four-stage monitoring cadence applies across the class. Compounded peptide preparations operate under AMA Code 1.1.5 framework with documented risk-benefit assessment and FDA-approved alternatives considered.

Strongest evidence

FDA prescribing information provides the strongest framework for FDA-approved peptide protocol design.

FDA prescribing information for FDA-approved peptide drugs provides the strongest framework for protocol design including duration limits and sequential therapy frameworks. The anabolic osteoporosis peptide class examples include Forteo teriparatide (NDA 021318) anchored in VERT NEJM 2001 (Neer et al.), Tymlos abaloparatide (NDA 208743) anchored in ACTIVE JAMA 2016 (Miller et al.), and Evenity romosozumab (NDA 761062 with cardiovascular boxed warning) anchored in FRAME NEJM 2016 (Cosman et al.) and ARCH NEJM 2017 (Saag et al.). The GLP-1 receptor agonist class examples include Wegovy and Ozempic semaglutide anchored in SELECT 2023 NEJM (Lincoff et al.), SUSTAIN-6 NEJM 2016, and STEP trial program. Zepbound and Mounjaro tirzepatide anchored in SURMOUNT-1 NEJM 2022 (Jastreboff et al.) and SURPASS trial program. Saxenda and Victoza liraglutide anchored in LEADER NEJM 2016. Tesamorelin Egrifta (NDA 022505) anchored in LIPO trials for HIV-associated lipodystrophy. Society Clinical Practice Guidelines anchor sequential therapy framework: AACE/ACE 2020 and Endocrine Society 2019 Postmenopausal Osteoporosis CPGs for anti-resorptive transition.

Limitations

Compounded peptide preparations operate outside FDA pre-market approval. Protocol design for compounded preparations requires AMA Code 1.1.5 framework documentation.

Compounded peptide preparations operate under the FDA Compounding Quality Act of 2013 without FDA pre-market approval. Protocol design for compounded preparations requires AMA Code 1.1.5 framework documentation including risk-benefit assessment and FDA-approved alternatives considered. Evidence base for compounded peptide preparations varies substantially across compounds and indications. Some compounded peptides operate at L3 human trials evidence tier in international approval contexts. Other compounded peptides operate at L1 to L2 evidence tier with primarily preclinical evidence. PSI provides conceptual education only and does not provide protocol design instructions, cycling guidance, or specific duration recommendations. Protocol design must be determined by a qualified physician. Patient-specific clinical context including age, sex, comorbidities, concurrent medications, prior peptide therapy history, and indication match all affect protocol decisions. Specialty coordination supports complex contexts.

Assessment

The framework establishes protocol design methodology anchored in FDA prescribing information and society Clinical Practice Guidelines.

PSI's reading: peptide therapy protocol design is anchored in FDA prescribing information for FDA-approved peptides and AMA Code of Medical Ethics 1.1.5 framework for compounded preparations. The anabolic osteoporosis peptide class has FDA-label-specified cumulative lifetime maximums (Forteo, Tymlos) and fixed monthly schedule framework (Evenity with cardiovascular boxed warning) with sequential anti-resorptive transition per society CPGs. The GLP-1 receptor agonist class supports ongoing therapy per FDA label with cardiovascular outcomes evidence anchoring continued therapy. The four-stage monitoring cadence applies across the class. AMA Code 1.1.5 framework provides ethical anchoring for compounded preparation protocol decisions. The PSI compound library provides FDA-approved peptide drug class information. The PSI physician directory provides verified physicians applying FDA prescribing information, AMA Code 1.1.5 framework, and society CPGs to clinical decisions. Specialty coordination across endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, men's health, and cardiology (for Evenity boxed warning context) supports comprehensive evaluation. PSI provides conceptual education only.

How to Approach Your Decision

Limitations and Caveats

This page is conceptual education only. PSI does not provide protocol design instructions, cycling guidance, or specific duration recommendations.
Protocol design must be determined by a qualified physician. Patient-specific clinical context affects all decisions.
FDA prescribing information varies by peptide drug and indication. Anabolic osteoporosis class differs from GLP-1 receptor agonist class.
Compounded peptide preparations operate outside FDA pre-market approval. AMA Code 1.1.5 framework documentation applies.
Patient-specific clinical context affects protocol decisions. Age, sex, comorbidities, concurrent medications, prior peptide therapy history matter.
Specialty coordination supports complex protocol contexts. Endocrinology, weight medicine, rheumatology, cardiology support contexts.
Cardiovascular boxed warnings affect protocol framework for specific compounds. Evenity romosozumab requires cardiology coordination per ARCH trial findings.
Sequential therapy transitions require physician evaluation. Anti-resorptive transition after anabolic peptide completion follows society CPG recommendations.

What's Marketed vs What's Studied

7 common claims, corrected.

“Patients can design their own peptide therapy cycles.”

Protocol design must be determined by the prescribing physician per FDA prescribing information for FDA-approved peptides and AMA Code 1.1.5 framework for compounded preparations. Patient-specific clinical context affects all decisions. PSI does not provide protocol design or cycling guidance.

“All peptide drugs have cumulative lifetime maximums.”

FDA prescribing information varies by peptide drug and class. The anabolic osteoporosis peptide class has cumulative lifetime maximums for Forteo and Tymlos per FDA label. The GLP-1 receptor agonist class supports ongoing therapy per FDA label without cumulative maximum. The physician applies FDA label per individual peptide drug.

“GLP-1 receptor agonist therapy is time-limited like anabolic osteoporosis peptide therapy.”

GLP-1 receptor agonist therapy supports ongoing chronic disease management per FDA label. SELECT 2023 NEJM demonstrated cardiovascular benefit with continued therapy. Discontinuation typically results in weight regain and metabolic regression per Phase 3 trial extension evidence.

“Evenity romosozumab is administered indefinitely.”

Evenity uses fixed monthly schedule per FDA label for a defined treatment course. The cardiovascular boxed warning reflects ARCH trial findings. Sequential anti-resorptive transition follows Evenity completion per AACE/ACE 2020 and Endocrine Society 2019 CPGs. The physician determines individual patient protocol.

“Anti-resorptive transition after anabolic peptide therapy is optional.”

AACE/ACE 2020 Postmenopausal Osteoporosis CPG and Endocrine Society 2019 CPG recommend sequential anti-resorptive transition after anabolic peptide therapy completion. The transition supports continued fracture risk reduction. The physician determines specific transition timing and agent.

“Self-sourcing peptides allows patients to design their own cycling protocols.”

Self-sourcing of peptide preparations outside physician prescribing pathways operates outside the validated clinical practice framework. Research-grade peptide products labeled not for human use are not a legal substitute for physician-prescribed therapy. Self-designed protocols operate outside AMA Code 1.1.5 framework.

“Compounded peptide preparations have the same protocol framework as FDA-approved peptides.”

Compounded peptide preparations operate under AMA Code 1.1.5 framework with physician-determined protocols per documented risk-benefit assessment. The framework requires FDA-approved alternatives considered per indication. Compounded protocol decisions are individualized per patient context.

Common Questions

How are peptide therapy protocols designed?

Peptide therapy protocols are designed by the prescribing physician per FDA prescribing information for FDA-approved peptides and AMA Code of Medical Ethics 1.1.5 framework for compounded preparations. The protocol design includes dosing, route, schedule, duration, monitoring, and sequential therapy framework. The physician applies FDA label and individual patient context.

What is the cumulative lifetime maximum for Forteo teriparatide?

Forteo teriparatide (NDA 021318) has an FDA-label-specified cumulative lifetime maximum. The framework reflects Phase 3 trial evidence from VERT NEJM 2001 (Neer et al.) and FDA approval considerations. The physician determines individual patient application per FDA label, AACE/ACE 2020 Postmenopausal Osteoporosis CPG, and Endocrine Society 2019 CPG framework.

What is the cumulative lifetime maximum for Tymlos abaloparatide?

Tymlos abaloparatide (NDA 208743) has an FDA-label-specified cumulative lifetime maximum. The framework reflects Phase 3 trial evidence from ACTIVE JAMA 2016 (Miller et al.) and FDA approval considerations. The physician determines individual patient application per FDA label, AACE/ACE 2020 framework, and individual clinical context.

How is Evenity romosozumab administered?

Evenity romosozumab (NDA 761062 with cardiovascular boxed warning) uses a fixed monthly schedule per FDA label for a defined treatment course. The framework reflects the dual-action mechanism increasing formation and decreasing resorption. Sequential anti-resorptive transition follows completion per AACE/ACE 2020 and Endocrine Society 2019 CPGs.

Why does Evenity have a cardiovascular boxed warning?

FDA added the cardiovascular boxed warning in April 2019 based on ARCH NEJM 2017 (Saag et al.) trial findings demonstrating increased serious cardiovascular adverse events compared to alendronate comparator. The boxed warning affects protocol framework. Specialty cardiology coordination supports the framework.

How long can GLP-1 receptor agonist therapy continue?

GLP-1 receptor agonist therapy supports ongoing therapy per FDA prescribing information without a label-specified cumulative lifetime maximum. SELECT 2023 NEJM demonstrated cardiovascular benefit with continued semaglutide therapy over multi-year follow-up. The physician determines individual patient duration per FDA label and clinical context.

What happens if GLP-1 receptor agonist therapy is discontinued?

Discontinuation typically results in weight regain and metabolic regression per Phase 3 trial extension evidence. STEP-4 extension trial demonstrated weight regain after semaglutide discontinuation supporting chronic disease management framework rather than time-limited intervention. Discuss any discontinuation decisions with your prescribing physician.

What is sequential anti-resorptive transition?

Sequential anti-resorptive transition follows anabolic osteoporosis peptide therapy completion per AACE/ACE 2020 Postmenopausal Osteoporosis CPG and Endocrine Society 2019 CPG. Anti-resorptive options include bisphosphonates (alendronate, risedronate, zoledronic acid) or denosumab. The transition supports continued fracture risk reduction after anabolic completion.

What is the four-stage monitoring cadence?

The four-stage monitoring cadence applies across peptide therapy. Stage 1 baseline at week 0 establishes the foundation. Stage 2 early follow-up at week 4 to 8 tracks tolerability. Stage 3 stabilization at month 3 captures steady-state response. Stage 4 maintenance at month 6 with annual continuation thereafter applies the full panel re-check.

How are compounded peptide preparation protocols designed?

Compounded peptide preparation protocols operate under AMA Code of Medical Ethics 1.1.5 framework with physician-determined design per documented risk-benefit assessment. The framework requires FDA-approved alternatives considered per indication. Monitoring requirements and patient understanding through informed consent apply.

Does PSI provide cycling protocols for compounded peptides?

No. PSI provides conceptual education only and does not provide protocol design instructions, cycling guidance, or specific duration recommendations. Compounded peptide preparation protocols must be determined by a qualified physician applying AMA Code 1.1.5 framework. PSI does not provide personalized protocol guidance.

What is AMA Code of Medical Ethics 1.1.5?

AMA Code of Medical Ethics Opinion 1.1.5 (Off-Label and Investigational Use of Pharmaceuticals) governs off-label and compounded prescribing decisions. The framework requires documented risk-benefit assessment for the specific patient context, FDA-approved alternatives considered, monitoring requirements, and patient understanding through informed consent acknowledgment.

Can patients design their own peptide therapy protocols?

No. Protocol design must be determined by the prescribing physician per FDA prescribing information and individual patient context. Self-designed protocols operate outside the validated clinical practice framework. AMA Code 1.1.5 framework applies for compounded preparations. PSI does not provide protocol design guidance.

Where can I find a physician for peptide therapy protocol design?

The PSI physician directory provides verified physicians across major US cities with peptide therapy experience. Verification includes state medical board license verification, ABMS board certification, and AMA Code 1.1.5 documentation practice. Specialty coordination supports indication-specific contexts.

What specialty coordination supports peptide therapy protocols?

Specialty coordination spans endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, men's health, and cardiology (for Evenity boxed warning context). The PSI physician directory provides verified physicians across specialties.

How are protocol changes documented?

Protocol changes are documented per the prescribing physician's clinical practice including changes in dose, route, schedule, or sequential therapy. For compounded preparations, AMA Code 1.1.5 framework documentation includes risk-benefit re-assessment, FDA-approved alternatives re-considered, and updated monitoring requirements. Discuss any protocol change decisions with your physician.

Sourcing Checklist

Obtain peptide therapy through physician prescription with documented protocol design.
Self-designed protocols operate outside the validated clinical practice framework. AMA Code 1.1.5 documentation framework applies for compounded prescribing.
Expect FDA prescribing information match for FDA-approved peptide drug protocol framework.
Wegovy, Ozempic, Zepbound, Mounjaro support ongoing therapy. Forteo, Tymlos have cumulative lifetime maximums. Evenity uses fixed monthly schedule.
Confirm AMA Code 1.1.5 documentation for compounded preparation protocol design.
Documentation includes risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding through informed consent.
Expect sequential anti-resorptive transition after anabolic osteoporosis peptide completion.
AACE/ACE 2020 and Endocrine Society 2019 CPGs recommend bisphosphonate or denosumab transition supporting continued fracture risk reduction.
Follow four-stage monitoring cadence: baseline, early follow-up, stabilization, maintenance.
Baseline week 0, early follow-up week 4-8, stabilization month 3, maintenance month 6 with annual continuation thereafter.
Expect cardiology coordination for Evenity romosozumab protocol framework.
The cardiovascular boxed warning reflects ARCH trial findings. Cardiology coordination supports protocol decisions for the cardiovascular risk context.
Expect specialty coordination for indication-specific protocol contexts.
Endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health support indication-appropriate framework.
Discuss protocol changes with prescribing physician for documented framework adjustment.
Protocol changes require documented re-assessment for AMA Code 1.1.5 compounded contexts. FDA-approved peptide protocol changes per FDA label.
Report serious adverse events through FDA MedWatch surveillance during peptide therapy.
MedWatch supports serious adverse event reporting for FDA-approved peptide drug class supporting ongoing safety signal monitoring.

Regulatory Context

FDA prescribing information for FDA-approved peptide drugs updates periodically with new clinical data, post-marketing surveillance findings, and label changes. AACE/ACE Postmenopausal Osteoporosis CPG and Endocrine Society Postmenopausal Osteoporosis CPG update on multi-year cycles. ADA Standards of Care updates annually. New FDA peptide approvals expand the FDA-approved class and protocol framework. AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks remain foundational. PSI tracks FDA prescribing information changes and society CPG updates per the Editorial Standards review cadence.

Comparison

Peptide Class	Duration Framework	Sequential Therapy	Society CPG Anchor
Anabolic osteoporosis (Forteo)	FDA-label-specified cumulative lifetime maximum	Anti-resorptive transition after completion	AACE/ACE 2020, Endocrine Society 2019
Anabolic osteoporosis (Tymlos)	FDA-label-specified cumulative lifetime maximum	Anti-resorptive transition after completion	AACE/ACE 2020, Endocrine Society 2019
Sclerostin antibody (Evenity)	Fixed monthly schedule per FDA label (with CV boxed warning)	Anti-resorptive transition after completion	AACE/ACE 2020, Endocrine Society 2019
GLP-1 receptor agonist (Wegovy, Ozempic)	Ongoing therapy per FDA label	Chronic disease management framework	ADA 2024 Standards of Care
GLP-1 receptor agonist (Zepbound, Mounjaro)	Ongoing therapy per FDA label	Chronic disease management framework	ADA 2024 Standards of Care
GH secretagogue (Tesamorelin)	Ongoing per FDA label for HIV-associated lipodystrophy	Per FDA prescribing information	Indication-specific framework
Sexual health (Vyleesi)	On-demand per FDA label	Per FDA prescribing information	Indication-specific framework
Compounded preparation	AMA Code 1.1.5 framework	Per physician documentation	Off-label and compounded prescribing framework

Who This Applies To

· Postmenopausal woman with high fracture risk osteoporosis considering anabolic peptide therapy protocol framework.
· Adult considering Forteo or Tymlos and reviewing FDA-label-specified cumulative lifetime maximum framework.
· Postmenopausal woman considering Evenity and reviewing fixed monthly schedule with anti-resorptive transition.
· Adult considering GLP-1 receptor agonist therapy and reviewing ongoing therapy framework per FDA label.
· Patient evaluating sequential anti-resorptive transition framework after anabolic peptide completion.
· Adult considering compounded peptide therapy and reviewing AMA Code 1.1.5 framework for protocol design.
· Patient reviewing four-stage monitoring cadence framework before peptide therapy initiation.
· Adult with established cardiovascular disease considering Evenity and reviewing cardiology coordination context.
· Adult with type 2 diabetes considering ongoing GLP-1 receptor agonist therapy per ADA 2024 Standards of Care.
· Patient considering protocol changes during peptide therapy and reviewing physician documentation framework.

Verdict

Peptide therapy protocol design is determined by the prescribing physician. The framework anchors in FDA prescribing information and AMA Code 1.1.5 for compounded preparations. The anabolic osteoporosis peptide class has FDA-label-specified cumulative lifetime maximums with sequential anti-resorptive transition. The GLP-1 receptor agonist class supports ongoing therapy. The four-stage monitoring cadence applies across the class. PSI provides conceptual education only. Protocol design must be determined by a qualified physician evaluating individual patient context.

In Plain Terms

Peptide therapy protocols are designed by your doctor. The FDA label tells your doctor the duration framework. For osteoporosis peptides like Forteo and Tymlos, the FDA label sets a lifetime maximum. For Evenity, the FDA label sets a fixed monthly schedule. After completing these, your doctor transitions you to a bisphosphonate or denosumab. For GLP-1 drugs like Wegovy and Ozempic, the FDA label supports ongoing therapy. Your doctor decides the right protocol based on the FDA label and your situation. PSI does not give cycling instructions.

Different peptide drugs have different protocol frameworks. Some have lifetime maximums set by the FDA label. Some support ongoing therapy. Your doctor decides the right framework based on the FDA label and your individual situation. For osteoporosis peptides, your doctor switches you to a bisphosphonate after completing the anabolic phase. For GLP-1 drugs, your doctor continues therapy as long as it benefits you. Always work with your prescribing physician on protocol design.

Peptide therapy protocol design requires physician-determined framework per FDA prescribing information for FDA-approved peptides and AMA Code 1.1.5 framework for compounded preparations. The PSI physician directory provides verified physicians with peptide therapy experience supporting individualized protocol design across endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, men's health, and cardiology.

Find a verified physician

PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.

Browse the directory Learn about the verification process →

Related Conditions

Related Education

Featured Compounds

Common Contexts

· Postmenopausal woman with high fracture risk considering anabolic peptide protocol
· Adult considering Forteo or Tymlos and reviewing cumulative lifetime maximum
· Postmenopausal woman considering Evenity and reviewing fixed monthly framework
· Adult considering GLP-1 receptor agonist and reviewing ongoing therapy framework
· Patient evaluating sequential anti-resorptive transition framework
· Adult considering compounded peptide and reviewing AMA Code 1.1.5 protocol framework
· Patient reviewing four-stage monitoring cadence framework
· Adult with established CV disease considering Evenity and cardiology coordination
· Adult with type 2 diabetes considering ongoing GLP-1 therapy
· Patient considering protocol changes during peptide therapy

Important Context

This page is educational and does not constitute medical advice. The information presented reflects FDA prescribing information for FDA-approved peptide drugs (Wegovy NDA 215256, Ozempic NDA 209637, Zepbound NDA 217806, Mounjaro NDA 215866, Forteo NDA 021318, Tymlos NDA 208743, Evenity NDA 761062 with cardiovascular boxed warning, Tesamorelin Egrifta NDA 022505, Vyleesi NDA 210557), society Clinical Practice Guidelines (AACE/ACE 2020 Postmenopausal Osteoporosis CPG, Endocrine Society 2019 CPG, ADA 2024 Standards of Care), AMA Code of Medical Ethics 1.1.5 (Off-Label and Investigational Use of Pharmaceuticals) and 2.1.1 (Informed Consent) frameworks, FDA Compounding Quality Act of 2013, and cardiovascular outcomes trial evidence including SELECT 2023, SUSTAIN-6, LEADER, VERT, ACTIVE, FRAME, and ARCH. This page provides conceptual education only and does not provide protocol design instructions, cycling guidance, or specific duration recommendations.

Your physician will determine the appropriate peptide therapy protocol design, duration, and sequential therapy framework per FDA prescribing information for FDA-approved peptides and AMA Code 1.1.5 framework for compounded preparations. The framework described here is general and does not substitute for individualized clinical judgment. Specialty coordination supports complex contexts across primary care, endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, men's health, and cardiology (for Evenity boxed warning context).

Self-designed peptide protocols without prescribing physician guidance and clinical oversight are not appropriate. The prescribing physician determines protocol design, duration, and sequential therapy per FDA prescribing information and individual patient context. Self-sourcing of peptide preparations outside physician prescribing pathways operates outside the validated clinical practice framework. Research-grade peptide products labeled not for human use are not a legal substitute for physician-prescribed FDA-approved or compounded therapy.

Educational content only. This page provides conceptual education about FDA-approved peptide therapy protocol design framework. PSI does not provide protocol design instructions, cycling guidance, or specific duration recommendations. Dosing and protocol design should be determined by a qualified physician who can evaluate your individual situation. PSI does not provide personalized clinical recommendations. Discuss with your physician before initiating any peptide therapy.

Sources and Citations

[1] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
[2] FDA Prescribing Information: Tymlos (abaloparatide) injection · 2022 · FDA NDA 208743 · Source
[3] FDA Prescribing Information: Evenity (romosozumab-aqqg) injection with cardiovascular boxed warning · 2019 · FDA NDA 761062 · Source
[4] FDA Prescribing Information: Wegovy (semaglutide) injection · 2024 · FDA NDA 215256 · Source
[5] FDA Prescribing Information: Zepbound (tirzepatide) injection · 2024 · FDA NDA 217806 · Source
[6] FDA Prescribing Information: Egrifta (tesamorelin) for HIV-associated lipodystrophy · 2023 · FDA NDA 022505 · Source
[7] Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis (VERT trial) · New England Journal of Medicine · 2001 · DOI
[8] Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis (ACTIVE trial) · JAMA · 2016 · DOI
[9] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI
[10] Camacho PM, Petak SM, Binkley N, et al. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis 2020 Update · Endocrine Practice · 2020 · DOI
[11] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
[12] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.